Sentences with phrase «tumor heterogeneity in»

Tumor heterogeneity in solid tumor cancers impacts clonal evolution and patient outcomes.

Not exact matches

Interest in liquid biopsy has escalated in recent years due to the minimally invasive sampling method, potential to overcome the challenges of tumor heterogeneity, and the potential for longitudinal monitoring of tumor burden through serial sampling.

In conclusion, this new study identifies the cellular origin of Pik3ca - induced tumours and reveals that oncogenic Pik3ca activates a multipotent genetic program, setting the stage for future intratumoural heterogeneity at the earliest stage of tumor development.

One of the key questions in cancer biology is to understand the mechanisms that control tumor heterogeneity and to determine to which extend tumor heterogeneity influences clinical outcome.

This is particularly true for immunotherapy, in which characterization of tumor heterogeneity is essential for choosing the most effective therapy.

This same feature, tumor heterogeneity, may reduce the ability to identify critical gene expression changes when comparing mean gene expression in adjacent tumor and normal tissues, as tumors of the same type may have different sets of genes differentially expressed.

He said that genetic and morphological heterogeneity within populations of animal cells is an emerging phenomenon and has been observed in tumor populations.

«Because the tumors develop spontaneously, there is heterogeneity in that tumor population, as a human being would have.

My research interests include computational methods for analyzing tumor heterogeneity, driver gene identification in cancer, and detecting bias in biological network analyses.

Decipher the molecular basis of cancer & better understand tumor heterogeneity by discovering more variants in a single assay.

With respect to biological applications, the group is focusing on how cellular heterogeneity and cell - to - cell communication drive ensemble - level decision - making in the immune system, with an emphasis on «two - body» interaction (e.g., host cell - virus interactions, innate immune control of adaptive immunity, tumor infiltration by immune cells).

Our PDX models and other next - generation cancer modeling platforms allow you to address critical questions in oncology research, such as unexplained drug resistance, drug efficacy, genomic heterogeneity in solid tumor, and the role of the immune system in drug response.

The understanding of cell identity, heterogeneity and plasticity in neuroblastoma has strong implications with respect to the development of new therapeutic strategies to eradicate tumor cells in neuroblastoma patients.

It is an enigmatic tumor presenting with a great genetic and clinical heterogeneity, both in terms of presentation and outcome.

More recently, he has focused on triple - negative breast cancer, the role of micro-RNAs in cancer growth and metastasis, tumor heterogeneity and novel approaches to targeting therapy - resistant breast cancers.

The degree of heterogeneity did not differ between primary and metastatic sites, indicating that more than one core biopsy, or even an entire tumor block might be needed to determine PD - L1 expression in a tumor.

Tissue heterogeneity in PD - L1 expression in both primary and metastatic sites indicates that a single core biopsy might not be sufficient to determine tumor PD - L1 expression.

Carrie Bhang is a research investigator in In Vivo Pharmacology at Novartis Oncology and is particularly interested in applying what we have learned about tumor heterogeneity to drug discovery and the development of combination therapiein In Vivo Pharmacology at Novartis Oncology and is particularly interested in applying what we have learned about tumor heterogeneity to drug discovery and the development of combination therapieIn Vivo Pharmacology at Novartis Oncology and is particularly interested in applying what we have learned about tumor heterogeneity to drug discovery and the development of combination therapiein applying what we have learned about tumor heterogeneity to drug discovery and the development of combination therapies.

[16] Second, we investigated the degree of tumor heterogeneity, which has been shown to be quite significant in primary kidney cancer [33].

[25] Seeing that in metastatic patients the only available tumor is often core biopsies rather than whole tissue blocks, we next attempted to determine whether the degree of heterogeneity varies between primary and metastatic sites, using the TMA cores as surrogates for core biopsy specimens.

Within a given tumor, variable PD - L1 staining heterogeneity was seen, however the degree of heterogeneity was similar in primary and metastatic sites (P = 0.482).

By means of a non-obese diabetic / severe combined immunodeficiency disease (NOD / SCID) xenotransplant assay in combination with specific cell surface markers (CD44 + CD24 - / low), CSCs were enriched from metastatic and primary breast tumors and were shown to have the ability to reestablish tumor heterogeneity after transplantation [1].

This is to accommodate small variants that occur at sites of copy number variation as well as in samples that are not pure: for example, due to tumor heterogeneity or sample mosaicism.

Tumor heterogeneity and interindividual differences may be reflected in diverse expression of proteins resulting in variable immunohistochemical staining patterns.

He's studying how tumor heterogeneity affects treatment and the role of microRNAs in pediatric cancers and leukemia.

He's interested in the heterogeneity seen in some tumors — specifically, when cells respond to treatments differently even though they share the same DNA.

My studies of cancer genomes have led to characterization of multiple pediatric and adult tumor types, to development of methods that identify and characterize changes in genomic heterogeneity, to defining acquired resistance mechanisms to targeted therapies and to designing novel, personalized vaccines for individual patients.

The Ignatius laboratory is interested in understanding the effects of tumor heterogeneity on relapse and resistance to therapies in Rhabdomyosarcoma and other sarcomas.

In vivo imaging of tumor - propagating cells, regional tumor heterogeneity, and dynamic cell movements in embryonal rhabdomyosarcomIn vivo imaging of tumor - propagating cells, regional tumor heterogeneity, and dynamic cell movements in embryonal rhabdomyosarcomin embryonal rhabdomyosarcoma.

Discover novel treatments in relapsed pediatric cancer by defining tumor heterogeneity and its effect on self - renewal and metastasis.

Cellular heterogeneity in solid tumor cancers impacts clonal evolution and patient outcomes.

Funding Agency CPRIT - First Time Tenure Track Award Title Understanding Functional Heterogeneity in Sarcomas Status Active Active Period 2016 Role Principal Investigator Grant Detail Relapse is the major problem in the clinic and understanding how tumors change or evolve at relapse is the focus of this grant.

However, he did discuss the continuing challenge of mutation heterogeneity in tumors — we can no longer refer to mutations as present or absent, but instead should report their frequency, which represents the proportion of clones with each mutation.

In tumor samples, where we frequently encounter variants with a very small allele frequency due to contamination with normal tissue, copy number variation, and tumor heterogeneity, high coverage is essential for accurate detection of these variants with high power.

Since heterogeneity in the tumor microenvironment, such as the presence of a neighboring blood vessel, may drive genetic changes, he reasoned that it might also be reflected on the level of proteins.

Although many posit that tumor cell heterogeneity is of a genetic basis associated with inherent high genomic instability in tumor cells, the heterogeneous cellular composition in tumors has also been hypothesized, early on, to be the consequence of abnormal tumor stem cell differentiation (9).

To translate advances in our understanding of molecular mechanisms of oncogenesis and tumor progression into novel therapeutic strategies.With primary focus on lung cancer, melanoma, and lymphoma / leukemia, we will use the strength of in - depth molecular and phenotypic characterization of tumor heterogeneity to identify new targets and translate those into new therapeutic opportunities.

In these cases, UroSEEK could be detecting clonal proliferations in the bladder epithelium that did not progress to cancer, and such proliferations may be more common in patients with BC than in the general population Risques and Kennedy, 2018Because only one biopsy from the primary tumor was available for comparison, it is also possible that intratumoral heterogeneity explains some of the discrepancieIn these cases, UroSEEK could be detecting clonal proliferations in the bladder epithelium that did not progress to cancer, and such proliferations may be more common in patients with BC than in the general population Risques and Kennedy, 2018Because only one biopsy from the primary tumor was available for comparison, it is also possible that intratumoral heterogeneity explains some of the discrepanciein the bladder epithelium that did not progress to cancer, and such proliferations may be more common in patients with BC than in the general population Risques and Kennedy, 2018Because only one biopsy from the primary tumor was available for comparison, it is also possible that intratumoral heterogeneity explains some of the discrepanciein patients with BC than in the general population Risques and Kennedy, 2018Because only one biopsy from the primary tumor was available for comparison, it is also possible that intratumoral heterogeneity explains some of the discrepanciein the general population Risques and Kennedy, 2018Because only one biopsy from the primary tumor was available for comparison, it is also possible that intratumoral heterogeneity explains some of the discrepancies.

Modeling mRNA expression heterogeneity in tumors through bimodal profiles is a novel powerful approach with the potential to uncover therapeutic targets that benefit subsets of cancer patients.

However, largescale studies have demonstrated that patient heterogeneity in the regulatory make - up of tumors remain.

Here, we present a new statistical approach called oncomix, that models transcriptional heterogeneity in tumor and adjacent normal (i.e. tumor - free) using bimodality to find oncogene candidates.